Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

Use of semaglutide results in steatohepatitis resolution and improved biochemical and imaging markers among patients with metabolic dysfunction-associated steatotic liver disease (MASLD), results of a meta-analysis have shown.

Semaglutide works wonders in MASH, MASLD

02 Sep 2026

More migraine-free days with rimegepant

02 Sep 2026 bởi

The CGRP* receptor antagonist rimegepant provides consistent pain relief and improves function in patients with migraine, as shown in the CONFIDENCE trial presented at EAN 2026.

More migraine-free days with rimegepant

02 Sep 2026

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 July 2026)

02 Sep 2026

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

02 Sep 2026 bởi

Antidiabetic drugs may exert effects beyond glycaemic control and could influence neurodegenerative risk, with sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) being associated with lower risk of Parkinson’s disease (PD), suggesting potential neuroprotective effects, a Bayesian network meta-analysis has found.

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

02 Sep 2026

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026 bởi

Among treatment-naïve adults with HIV who are initiating antiretroviral therapy (ART), a regimen containing doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF) is as good as the dolutegravir, emtricitabine, and tenofovir alafenamide (DTG/FTC/TAF) regimen in terms of viral suppression but is associated with less weight gain, according to the open-label, head-to-head OPTI-DOR study conducted in South Africa.

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

01 Sep 2026

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

A survey conducted prior to resmetirom approval reports low rates of weight loss medication prescription due to low comfort potentially from lack of education despite strong beliefs that these drugs can benefit patients with metabolic dysfunction-associated steatotic liver disease (MASLD).

Weight loss medications rarely prescribed in patients with MASLD: study

01 Sep 2026

Atogepant tied to better outcomes in adults with migraine

01 Sep 2026 bởi

In a subgroup of patients with migraine who completed the full 24-week double-blind treatment period, referred to as treatment completers, treatment with atogepant is associated with greater improvements in clinical efficacy and functional endpoints than topiramate, according to a post hoc analysis of the TEMPLE trial presented at EAN 2026.

Atogepant tied to better outcomes in adults with migraine

01 Sep 2026

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026 bởi

First-line combination treatment with docetaxel plus androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) or poly(ADP-ribose) polymerase inhibitor (PARPi) plus ARPI plus ADT results in clinically relevant but not statistically significant improvements in progression-free survival (PFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), a study has found.

Intensified triplet regimens may improve PFS in mHSPC

01 Sep 2026

Tenofovir-sparing ART carries HBV risks

31 Aug 2026 bởi

Discontinuing tenofovir in antiretroviral therapy (ART) may expose people living with HIV to hepatitis B virus (HBV)-related risks, including reactivation in those previously exposed and infection in those who are susceptible, according to a systematic review and meta-analysis.

Tenofovir-sparing ART carries HBV risks

31 Aug 2026

Novel Nav1.8 inhibitor reduces pain following abdominoplasty

30 Aug 2026

For patients undergoing abdominoplasty, treatment with the investigational Nav1.8 inhibitor helps relieve postoperative pain, as shown in a phase IIb trial.

Novel Nav1.8 inhibitor reduces pain following abdominoplasty

30 Aug 2026

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

Semaglutide works wonders in MASH, MASLD

Semaglutide works wonders in MASH, MASLD

More migraine-free days with rimegepant

More migraine-free days with rimegepant

Original New Drug Application Approvals by US FDA (16-31 July 2026)

Original New Drug Application Approvals by US FDA (16-31 July 2026)

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

SGLT2i & GLP-1 RA may protect against Parkinson’s disease

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

Doravirine-based ART matches dolutegravir-based regimen in efficacy with less weight gain

Weight loss medications rarely prescribed in patients with MASLD: study

Weight loss medications rarely prescribed in patients with MASLD: study

Atogepant tied to better outcomes in adults with migraine

Atogepant tied to better outcomes in adults with migraine

Intensified triplet regimens may improve PFS in mHSPC

Intensified triplet regimens may improve PFS in mHSPC

Tenofovir-sparing ART carries HBV risks

Tenofovir-sparing ART carries HBV risks

Novel Nav1.8 inhibitor reduces pain following abdominoplasty

Novel Nav1.8 inhibitor reduces pain following abdominoplasty